Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.17
BCRX's Cash to Debt is ranked lower than
78% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. BCRX: 1.17 )
Ranked among companies with meaningful Cash to Debt only.
BCRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.94  Med: No Debt Max: 11087.67
Current: 1.17
0.94
11087.67
Equity to Asset 0.16
BCRX's Equity to Asset is ranked lower than
88% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BCRX: 0.16 )
Ranked among companies with meaningful Equity to Asset only.
BCRX' s Equity to Asset Range Over the Past 10 Years
Min: -0.23  Med: 0.61 Max: 0.98
Current: 0.16
-0.23
0.98
F-Score: 2
Z-Score: -9.19
M-Score: -3.06
WACC vs ROIC
12.77%
-325.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -244.22
BCRX's Operating margin (%) is ranked lower than
61% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. BCRX: -244.22 )
Ranked among companies with meaningful Operating margin (%) only.
BCRX' s Operating margin (%) Range Over the Past 10 Years
Min: -756.28  Med: -105.32 Max: -18.42
Current: -244.22
-756.28
-18.42
Net-margin (%) -285.24
BCRX's Net-margin (%) is ranked lower than
64% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -81.84 vs. BCRX: -285.24 )
Ranked among companies with meaningful Net-margin (%) only.
BCRX' s Net-margin (%) Range Over the Past 10 Years
Min: -702.16  Med: -118.9 Max: -18.03
Current: -285.24
-702.16
-18.03
ROE (%) -156.89
BCRX's ROE (%) is ranked lower than
89% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: -31.92 vs. BCRX: -156.89 )
Ranked among companies with meaningful ROE (%) only.
BCRX' s ROE (%) Range Over the Past 10 Years
Min: -544.61  Med: -69.75 Max: -20.28
Current: -156.89
-544.61
-20.28
ROA (%) -60.01
BCRX's ROA (%) is ranked lower than
75% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. BCRX: -60.01 )
Ranked among companies with meaningful ROA (%) only.
BCRX' s ROA (%) Range Over the Past 10 Years
Min: -60.01  Med: -40.79 Max: -11.86
Current: -60.01
-60.01
-11.86
ROC (Joel Greenblatt) (%) -1286.00
BCRX's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. BCRX: -1286.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BCRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -15669.01  Med: -836.04 Max: -202.66
Current: -1286
-15669.01
-202.66
Revenue Growth (3Y)(%) 7.60
BCRX's Revenue Growth (3Y)(%) is ranked higher than
58% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. BCRX: 7.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BCRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -70.7  Med: -13.6 Max: 528
Current: 7.6
-70.7
528
EBITDA Growth (3Y)(%) -8.90
BCRX's EBITDA Growth (3Y)(%) is ranked lower than
60% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. BCRX: -8.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BCRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.9  Med: -8.9 Max: 63.7
Current: -8.9
-41.9
63.7
EPS Growth (3Y)(%) -9.30
BCRX's EPS Growth (3Y)(%) is ranked lower than
56% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. BCRX: -9.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BCRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.4  Med: -5.1 Max: 52.1
Current: -9.3
-38.4
52.1
» BCRX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BCRX Guru Trades in Q3 2015

Paul Tudor Jones 29,535 sh (+121.93%)
Steven Cohen Sold Out
» More
Q4 2015

BCRX Guru Trades in Q4 2015

Joel Greenblatt 19,424 sh (New)
Jim Simons 142,903 sh (New)
Paul Tudor Jones 11,185 sh (-62.13%)
» More
Q1 2016

BCRX Guru Trades in Q1 2016

John Paulson 263,100 sh (New)
Chuck Royce 160,000 sh (New)
Paul Tudor Jones 125,588 sh (+1022.83%)
Jim Simons 292,221 sh (+104.49%)
Joel Greenblatt Sold Out
» More
Q2 2016

BCRX Guru Trades in Q2 2016

John Paulson 263,100 sh (unchged)
Chuck Royce 160,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 16,687 sh (-86.71%)
» More
» Details

Insider Trades

Latest Guru Trades with BCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:AKBA, AMEX:BTX, NAS:PRTK, NAS:SGMO, NAS:OMED, NAS:MESO, NAS:LJPC, NAS:CRVS, NAS:PETX, NAS:NLNK, NAS:NSTG, NAS:RGNX, OTCPK:VNLPY, NAS:SQNM, NAS:VYGR, NAS:SVA, OTCPK:ELVAF, NAS:TGTX, NAS:CGEN, NAS:PTCT » details
Traded in other countries:BO1.Germany,
Biocryst Pharmaceuticals Inc is a biotechnology company. The Company designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

Biocryst Pharmaceuticals Inc. is a Delaware corporation originally founded in 1986. The Company is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include Peramivir, BCX4161, Two 2nd generation HAE compounds, BCX4430, Forodesine and Ulodesine. Peramivir is a neuraminidase inhibitor for the treatment of patients with influenza and a potent, intravenously administered antiviral agent that rapidly delivers high plasma concentrations to the sites of infection. BCX4161 is a novel, selective inhibitor of plasma kallikrein in development as an orally-administered treatment for the prevention of attacks in patients with Hereditary Angioedema. Forodesine is a PNP inhibitor in development as a treatment for cancer. Ulodesine is a PNP inhibitor developed as a once-daily oral, chronic treatment for gout. The Company's product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.

Ratios

vs
industry
vs
history
P/B 22.97
BCRX's P/B is ranked lower than
93% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: 3.67 vs. BCRX: 22.97 )
Ranked among companies with meaningful P/B only.
BCRX' s P/B Range Over the Past 10 Years
Min: 1.05  Med: 8.22 Max: 126.72
Current: 22.97
1.05
126.72
P/S 12.19
BCRX's P/S is ranked lower than
52% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.30 vs. BCRX: 12.19 )
Ranked among companies with meaningful P/S only.
BCRX' s P/S Range Over the Past 10 Years
Min: 0.66  Med: 7 Max: 3333.33
Current: 12.19
0.66
3333.33
Current Ratio 0.82
BCRX's Current Ratio is ranked lower than
89% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. BCRX: 0.82 )
Ranked among companies with meaningful Current Ratio only.
BCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.8  Med: 5.77 Max: 39.53
Current: 0.82
0.8
39.53
Quick Ratio 0.79
BCRX's Quick Ratio is ranked lower than
86% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. BCRX: 0.79 )
Ranked among companies with meaningful Quick Ratio only.
BCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.77  Med: 5.74 Max: 39.53
Current: 0.79
0.77
39.53
Days Inventory 335.61
BCRX's Days Inventory is ranked lower than
86% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 132.42 vs. BCRX: 335.61 )
Ranked among companies with meaningful Days Inventory only.
BCRX' s Days Inventory Range Over the Past 10 Years
Min: 220.91  Med: 363.62 Max: 15234.51
Current: 335.61
220.91
15234.51
Days Sales Outstanding 32.36
BCRX's Days Sales Outstanding is ranked higher than
75% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. BCRX: 32.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.36  Med: 146.02 Max: 267.7
Current: 32.36
32.36
267.7
Days Payable 1.00
BCRX's Days Payable is ranked lower than
93% of the 422 Companies
in the Global Biotechnology industry.

( Industry Median: 53.36 vs. BCRX: 1.00 )
Ranked among companies with meaningful Days Payable only.
BCRX' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 9756.18 Max: 34806.57
Current: 1
1
34806.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.00
BCRX's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. BCRX: -13.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.4  Med: -8.3 Max: -0.6
Current: -13
-20.4
-0.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 22.97
BCRX's Price/Tangible Book is ranked lower than
90% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. BCRX: 22.97 )
Ranked among companies with meaningful Price/Tangible Book only.
BCRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.33  Med: 4.33 Max: 125.52
Current: 22.97
0.33
125.52
Price/Median PS Value 1.74
BCRX's Price/Median PS Value is ranked lower than
79% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. BCRX: 1.74 )
Ranked among companies with meaningful Price/Median PS Value only.
BCRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 2.46 Max: 418.75
Current: 1.74
0.13
418.75
Earnings Yield (Greenblatt) (%) -21.90
BCRX's Earnings Yield (Greenblatt) (%) is ranked lower than
71% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. BCRX: -21.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BCRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -21.9  Med: 487.1 Max: 1563.9
Current: -21.9
-21.9
1563.9

More Statistics

Revenue (TTM) (Mil) $25.20
EPS (TTM) $ -0.98
Beta1.44
Short Percentage of Float13.78%
52-Week Range $1.63 - 14.00
Shares Outstanding (Mil)73.70

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 22 17 10
EPS ($) -0.99 -1.27 -1.16
EPS w/o NRI ($) -0.99 -1.27 -1.16
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,249 Shares Apr 06 2010 

More From Other Websites
Biocryst Pharmaceuticals Inc (BCRX): Billionaire David E. Shaw’s Fund Increases Stake Aug 23 2016
BIOCRYST PHARMACEUTICALS INC Financials Aug 17 2016
Biocryst Pharmaceuticals Inc (BCRX): Baker Bros. Advisors Unloads Nearly 4 Million Shares Aug 17 2016
ETF’s with exposure to BioCryst Pharmaceuticals, Inc. : August 15, 2016 Aug 15 2016
BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12,... Aug 12 2016
BioCryst Pharma upgraded by Piper Jaffray Aug 12 2016
BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema Aug 11 2016
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 11 2016
BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema Aug 11 2016
Bulls pile into Biocryst Pharmaceuticals Aug 10 2016
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 18.1% Aug 10 2016
BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 08 2016
Watch these biotechs as the Zika virus moves to the U.S. Aug 06 2016
Edited Transcript of BCRX earnings conference call or presentation 4-Aug-16 3:00pm GMT Aug 05 2016
BioCryst reports 2Q loss Aug 04 2016
BioCryst reports 2Q loss Aug 04 2016
Try these good-times stocks in a market that’s going nowhere Aug 04 2016
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2016
BioCryst Reports Second Quarter 2016 Financial Results Aug 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)